NovoCure Ltd (NASDAQ: NVCR)’s stock price has increased by 1.84 compared to its previous closing price of 19.26. However, the company has seen a 2.85% increase in its stock price over the last five trading sessions. fool.com reported 2025-03-04 that Explore the exciting world of NovoCure (NVCR -1.20%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Is It Worth Investing in NovoCure Ltd (NASDAQ: NVCR) Right Now?
The stock has a 36-month beta value of 0.62. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for NVCR is 98.88M, and at present, short sellers hold a 5.26% of that float. On March 07, 2025, the average trading volume of NVCR was 1.00M shares.
NVCR’s Market Performance
The stock of NovoCure Ltd (NVCR) has seen a 2.85% increase in the past week, with a -18.88% drop in the past month, and a -35.71% fall in the past quarter. The volatility ratio for the week is 7.62%, and the volatility levels for the past 30 days are at 5.34% for NVCR. The simple moving average for the past 20 days is -5.56% for NVCR’s stock, with a -5.65% simple moving average for the past 200 days.
Analysts’ Opinion of NVCR
Many brokerage firms have already submitted their reports for NVCR stocks, with Evercore ISI repeating the rating for NVCR by listing it as a “Outperform.” The predicted price for NVCR in the upcoming period, according to Evercore ISI is $30 based on the research report published on December 02, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NVCR reach a price target of $30, previously predicting the price at $24. The rating they have provided for NVCR stocks is “Buy” according to the report published on October 16th, 2024.
JP Morgan gave a rating of “Neutral” to NVCR, setting the target price at $15 in the report published on November 20th of the previous year.
NVCR Trading at -20.58% from the 50-Day Moving Average
After a stumble in the market that brought NVCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.53% of loss for the given period.
Volatility was left at 5.34%, however, over the last 30 days, the volatility rate increased by 7.62%, as shares sank -14.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.19% lower at present.
During the last 5 trading sessions, NVCR rose by +3.07%, which changed the moving average for the period of 200-days by -10.62% in comparison to the 20-day moving average, which settled at $20.77. In addition, NovoCure Ltd saw -34.18% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVCR starting from Weinberg Uri, who sale 268 shares at the price of $18.92 back on Mar 03 ’25. After this action, Weinberg Uri now owns 166,243 shares of NovoCure Ltd, valued at $5,071 using the latest closing price.
Leonard Frank X, the EVP, Pres., Novocure Oncology of NovoCure Ltd, sale 2,527 shares at $18.54 during a trade that took place back on Mar 03 ’25, which means that Leonard Frank X is holding 143,673 shares at $46,841 based on the most recent closing price.
Stock Fundamentals for NVCR
Current profitability levels for the company are sitting at:
- -0.28 for the present operating margin
- 0.77 for the gross margin
The net margin for NovoCure Ltd stands at -0.28. The total capital return value is set at -0.35. Equity return is now at value -46.67, with -14.13 for asset returns.
Based on NovoCure Ltd (NVCR), the company’s capital structure generated 0.65 points at debt to capital in total, while cash flow to debt ratio is standing at -0.04.
Currently, EBITDA for the company is -109.58 million with net debt to EBITDA at -4.83. When we switch over and look at the enterprise to sales, we see a ratio of 4.42. The receivables turnover for the company is 5.93for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.46.
Conclusion
To sum up, NovoCure Ltd (NVCR) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
